October 7, 2016

Orexo – FDA Approves Unique Low Dosage of Zubsolv®

Orexo AB (publ.) announced today that it has received approval from the US Food and Drug Administration (FDA) of a new unique low dose, 0.7mg/0.18 mg, tablet of Zubsolv (buprenorphine/naloxone) sublingual tablet (CIII) for the treatment of opioid dependence. The new dosage is expected to be available in US pharmacies in early 2017.

Read the full news release from Orexo.